<DOC>
	<DOCNO>NCT00004899</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Bone marrow transplantation may able replace cell destroy chemotherapy . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness chemotherapy plus bone marrow transplantation filgrastim treat patient acute myelogenous leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Chemotherapy Plus Bone Marrow Transplantation Filgrastim Treating Patients With Acute Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall survival disease free survival patient acute myelogenous leukemia myelodysplastic syndrome treat busulfan etoposide follow autologous bone marrow transplantation filgrastim ( G-CSF ) . - Assess toxicity regimen patient population . - Assess hematologic effect toxicities G-CSF give set patient . - Determine whether G-CSF stimulates leukemic relapse patient . - Determine whether G-CSF affect platelet recovery set patient . OUTLINE : Patients stratify accord first , second , third remission . Patients undergo bone marrow collection . Patients receive oral busulfan every 6 hour 16 dos day -5 , -4 , -3 , -2 . Patients receive etoposide IV 4 hour day -4 , -3 , -2 . Bone marrow reinfused 36-48 hour last dose etoposide . Patients receive filgrastim ( G-CSF ) IV daily begin 2-4 hour bone marrow reinfusion hematopoietic recovery . Patients follow monthly 1 year , every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 20-30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically proven ( bone marrow aspirate smear touch prep marrow biopsy ) myelodysplastic syndrome acute myelogenous leukemia ( AML ) 1 follow subtypes : Acute myeloblastic leukemia ( FAB M1 M2 ) Acute promyelocytic leukemia ( FAB M3 ) Acute myelomonocytic leukemia ( FAB M4 ) Acute monocytic leukemia ( FAB M5 ) Acute erythroleukemia ( FAB M6 ) In complete remission time marrow stem cell harvest No relapse AML unless bone marrow peripheral blood stem cell previously harvest remission available transplantation May secondary AML either therapy relate evolve antecedent myelodysplastic syndrome History CNS disease induction allow provided inactive cytologic examination spinal fluid preharvest lumbar puncture show evidence leukemia No occult symptomatic leukemic meningitis induction therapy prior bone marrow harvest PATIENT CHARACTERISTICS : Age : Physiologic 65 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : Cardiac ejection fraction normal Pulmonary : FEV1 least 60 % predict DLCO least 60 % predict Other : HIV negative No evidence persistent infection No concurrent organ damage medical problem would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>